The first genomic alterations described in T-SCLC patient samples were biallelic inactivation of the RB1 and p53 tumor suppressors, which are observed in the majority of cases [7,9,11,12,13,23,43,44,55]. Here, TP53 is linked to small cell lung carcinoma.